金吾财讯 | 基石药业(02616)公布，拟配售最多8000万股配售股份，占经配发及发行所有配售股份扩大的已发行股本约5.86%。每股配售价格为2.933港元，较上交易日收市价折让约14.99%。假设所有配售股份悉数获配售，则配售估计所得款项总额及净额(扣除配售佣金及其他相关开支及专业费用后)将分别为约2.35亿港元及约2.32亿港元。每股配售股份的净配售价将为约2.904港元。配售所得款项净额预期将用于以下用途：(i)90%用于与集团“管线2.0”中的资产，尤其是CS5001(一款处于临床阶段的ROR1ADC(潜在同类最佳ROR1ADC))，以及CS2009(一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，潜在同类首创╱同类最优的下一代肿瘤免疫骨架)有关的进一步研发；及(ii)余下所得款项净额于适当时用于其他一般公司用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.